Drug Trial Radar · NCT05265286
A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Last checked: Nov 19, 2026Latest source record: May 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Apr 14, 2022
Primary completion
Aug 21, 2022
Study completion Aug 21, 2022
Sponsor
- Lead sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: To assess the pharmacokinetics, Safety and immunogenicity of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A(FRSW117) Secondary objectives: To assess Preliminary efficacy of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A.
Conditions
- Severe Hemophilia A
Interventions
FRSW117Drug
Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117. Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum measured concentration of FVIII:C (Cmax)Time frame: Pre-dose and post dose up to 10 days
- Time required for the concentration of the drug to reach half of its original value (T1/2)Time frame: Pre-dose and post dose up to 10 days
- Area Under the Curve to Infinity (AUC)Time frame: Pre-dose and post dose up to 10 days
- The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL)Time frame: Pre-dose and post dose up to 10 days
- Evaluation of the level of anti-PEG-rFⅧFc antibody production in participantsTime frame: Pre-dose and post dose up to 36 days
- Evaluation of the level of anti-PEG antibody production in participantsTime frame: Pre-dose and post dose up to 36 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
People'S Hospital of Zhengzhou
Zhengzhou, Henan, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
People'S Hospital of Rizhao
Rizhao, Shandong, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.